United Therapeutics enters the post-earnings period with an unusual alignment: options traders turned the most bullish they've been all year on the day the CEO and CFO were selling stock at the open.
The insider angle is the story of this week. On May 4, founder and CEO Martine Rothblatt sold roughly 3,680 shares across multiple tranches, collecting around $2.1 million at prices between $568 and $582. CFO James Edgemond sold an additional 3,485 shares worth approximately $2 million on the same day. The combined one-day figure of over $4 million in insider selling is notable — even if the 90-day net position for both executives remains net positive at $15.7 million when accounting for option-related activity over the quarter. The trade significance scores are low, suggesting pre-scheduled 10b5-1 plans are the most likely mechanism. Still, the timing — the day before the stock slipped 1.6% — adds colour.
Options positioning tells a completely different story from the insiders. The put/call ratio dropped to 0.74 on May 5, more than two standard deviations below its 20-day average of 0.83. That's the most call-heavy reading UTHR has seen in a year. Options traders are leaning hard into upside, not hedging against it. The Q1 earnings release landed that same morning, and the muted one-day stock reaction of +0.39% the prior session (April 29) and the 0.54% weekly gain suggest the print was broadly in line — neither a catalyst for fresh conviction nor a reason to exit. Quarterly revenue came in near $797 million with net income around $320 million and operating cash flow of $357 million. The company generates cash well in excess of its capex run-rate.
Short positioning is retreating rather than building. SI as a percentage of the free float has fallen to 6.0%, down 3.6% over the week and roughly back to where it was in early April before a brief mid-month spike above 6.5%. The ORTEX short score has drifted lower all week — 45.3 now versus 48.2 a fortnight ago — reflecting that squeeze pressure is fading, not intensifying. Borrow availability remains ample. Cost to borrow is running near a one-week high at 0.45% annualised, but that's a trivial carry cost for a short position. There is nothing in the lending market to suggest anyone is being forced out.
The Street has been broadly raising targets but stopping short of upgrades. Through late March and into April, multiple firms — including BofA, Wells Fargo, TD Cowen, HC Wainwright, and Cantor Fitzgerald — lifted price targets after the company reported its TETON-1 and TETON-2 data in pulmonary fibrosis. The most recent bellwether move was Morgan Stanley's Terence Flynn on April 10, who kept an Equal-Weight rating but raised his target to $519. With UTHR closing at $572, Flynn's target is already below market — a clear statement that not everyone on the Street believes the current premium is justified. The consensus mean target of $645 implies around 13% upside from here, but that figure is lifted by the more bullish Buy-rated houses. The valuation picture is undemanding by biotech standards: P/E sits near 18.5x, EV/EBITDA near 11.4x and compressing slightly over the past month. The stock is up 19% year-to-date.
Among correlated peers, the week was mixed. REGN lost 4% and VRTX gave back 1.3%, while ABBV added 4.3% and XENE gained 5.8%. UTHR's modest 0.5% weekly gain puts it squarely in the middle of the pack — neither the sector's standout performer nor its laggard.
Wellington Management stands out in the institutional register, having added over one million shares in the quarter to March 31, making it a 5.6% holder. That's a meaningful addition for an active manager of its profile. BlackRock and Vanguard hold the top two slots at 11.8% and 9.5% respectively, with both making small incremental additions — index-driven, not a directional call.
What to watch: the next confirmed event flag in the data reads "To Report Q1 2026 Results," suggesting the formal confirmation window is still open. Whether the post-earnings narrative sharpens around monotherapy positioning for nebulised Tyvaso in the no-background-therapy subgroup — the bear case's central concern — will determine whether the Street's target-raise cycle has further to run or has already captured the data-driven upside.
See the live data behind this article on ORTEX.
Open UTHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
